These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35994501)

  • 1. Differential progression of unhealthy diet-induced hepatocellular carcinoma in obese and non-obese mice.
    Hymel E; Vlock E; Fisher KW; Farazi PA
    PLoS One; 2022; 17(8):e0272623. PubMed ID: 35994501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential methylation patterns in lean and obese non-alcoholic steatohepatitis-associated hepatocellular carcinoma.
    Hymel E; Fisher KW; Farazi PA
    BMC Cancer; 2022 Dec; 22(1):1276. PubMed ID: 36474183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of Polyunsaturated Fatty Acids with Tumor Progression in a Lean Non-Alcoholic Steatohepatitis-Associated Hepatocellular Carcinoma Mouse Model.
    Vlock EM; Karanjit S; Talmon G; Farazi PA
    J Cancer; 2020; 11(19):5536-5546. PubMed ID: 32913449
    [No Abstract]   [Full Text] [Related]  

  • 4. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
    Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
    BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride.
    Li S; Motiño O; Lambertucci F; Chen H; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Maiuri MC; Kroemer G; Martins I
    Methods Mol Biol; 2024; 2769():57-65. PubMed ID: 38315388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
    Hansen HH; Pors S; Andersen MW; Vyberg M; Nøhr-Meldgaard J; Nielsen MH; Oró D; Madsen MR; Lewinska M; Møllerhøj MB; Madsen AN; Feigh M
    Sci Rep; 2023 Dec; 13(1):23056. PubMed ID: 38155202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.
    Sakuma T; Nakamura M; Chiba T; Iwanaga T; Kan M; Kojima R; Ao J; Ma Y; Unozawa H; Fujita N; Kanayama K; Kanzaki H; Koroki K; Kobayashi K; Nakagawa R; Kanogawa N; Kiyono S; Kondo T; Saito T; Ogasawara S; Nakamoto S; Muroyama R; Kato J; Kishimoto T; Kato N
    Lab Invest; 2022 Oct; 102(10):1150-1157. PubMed ID: 35643859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
    Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
    BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma.
    Vachher M; Bansal S; Kumar B; Yadav S; Arora T; Wali NM; Burman A
    J Cell Biochem; 2022 Oct; 123(10):1553-1584. PubMed ID: 35818831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
    Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle.
    Dowman JK; Hopkins LJ; Reynolds GM; Nikolaou N; Armstrong MJ; Shaw JC; Houlihan DD; Lalor PF; Tomlinson JW; Hübscher SG; Newsome PN
    Am J Pathol; 2014 May; 184(5):1550-61. PubMed ID: 24650559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
    Jump DB; Depner CM; Tripathy S; Lytle KA
    Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.